When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Neos Therapeutics (NEOS) made some hard choices over the last two years. The change at the top brought a change in strategic direction. The company cut costs viciously and decided to end unfavorable contracts with payers to boost the net price per pack (prescription) for its ADHD products Adzenys XR ODT and Cotempla XR ODT. The cost cuts significantly reduced the sales force, while ending unfavorable contracts reduced access for patients. But that part actually went well, and Neos managed to grow sales due to the higher net price for its products.